[1] 薛芮,范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志,2020,36(6):1224-1227. [2] Gofton C, Upendran Y, Zheng MH, et al.MAFLD: How is it different from NAFLD[J]. Clin Mol Hepatol, 2023, 29(9): S17-S31. [3] 史晓燕,潘萌. 姜黄素通过EZH2/PPAR γ途径抑制肝星状细胞活化[J]. 山西医科大学学报,2023,54(12):1577-1584. [4] 张斌,赵莹,陈建杰,等. 肝纤维化时肝脏OPN和PAI-1的表达变化[J]. 中国病理生理杂志,2010,26(7):1407-1409. [5] Diao H, Kon S, Iwabuchi K, et al.Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases[J]. Immunity, 2004, 21(4): 539-550. [6] Bousette N, Giaid A.Urotensin-II and cardiovascular diseases[J]. Curr Hypertens Rep, 2006, 8(6): 479-483. [7] Shiraishi Y, Watanabe T, Suguro T, et al.Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice[J]. J Hypertens, 2008, 26(10): 1955-1965. [8] Rocha VZ, Libby P.Obesity, inflammation, and atherosclerosis[J]. Nat Rev Cardiol, 2009, 6(6): 399-409. [9] 马威,杨家耀,安柳,等. 附子理中汤减轻非酒精性脂肪肝大鼠炎症损伤的机制研究[J]. 中国病理生理杂志,2020,36(12):2258-2263. [10] Li H, Zheng J, Xu Q, et al.Hepatocyte Adenosine Kinase Promotes Excessive Fat Deposition and Liver Inflammation[J]. Gastroenterology, 2023, 164(1): 134-146. [11] 鄢萍,黄中清,王丽宁,等. 非酒精性脂肪肝与动脉粥样硬化危险因素相关性调查[J]. 中国医药导报,2013,10(6):158-159,162. [12] Kawaguchi T, Tsutsumi T, Nakano D, et al.MAFLD: Renovation of clinical practice and disease awareness of fatty liver[J]. Hepatol Res, 2022, 52(5): 422-432. [13] Falk E.Pathogenesis of atherosclerosis[J]. J Am Coll Cardiol, 2006, 47(8): C7-12. [14] Younossi ZM, Koenig AB, Abdelatif D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. [15] Lancha A, Rodríguez A, Catalán V, et al.Osteopontin deletion prevents the development of obesity and hepatic steatosis via impaired adipose tissue matrix remodeling and reduced inflammation and fibrosis in adipose tissue and liver in mice[J]. PLoS One, 2014, 9(5): e98398. [16] Song Z, Chen W, Athavale D, et al.Osteopontin Takes Center Stage in Chronic Liver Disease[J]. Hepatology, 2021, 73(4): 1594-1608. [17] Xie G, Jiang R, Wang X, et al.Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis[J]. EbioMedicine, 2021, 66: 103290. [18] Maguire JJ, Davenport AP.Is urotensin-II the new endothelin[J]. Br J Pharmacol, 2002, 137(5): 579-588. [19] Papadopoulos P, Bousette N, Giaid A.Urotensin-II and cardiovascular remodeling[J]. Peptides, 2008, 29(5): 764-769. [20] Pereira-Castro J, Brás-Silva C, Fontes-Sousa AP.Novel insights into the role of urotensin II in cardiovascular disease[J]. Drug Discov Today, 2019, 24(11): 2170-2180. [21] Carotenuto A, Auriemma L, Merlino F, et al.Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor[J]. J Med Chem, 2014, 57(14): 5965-5974. |